Kitami A, Suzuki T, Kamio Y, Suzuki S
Department of Thoracic and Cardiovascular Surgery, Showa University Fujigaoka Hospital, Yokohama, Japan.
Jpn J Clin Oncol. 2001 Dec;31(12):601-4. doi: 10.1093/jjco/hye136.
Thymic carcinoma has a dismal prognosis compared with thymoma, because most of such tumors have locoregional invasion when diagnosed. Thus the important step in the management of thymic carcinoma is the introduction of systemic chemotherapy. However, as thymic carcinoma is a rare neoplasm, treatment with chemotherapy has not been studied systematically.
We analyzed seven cases of primary thymic carcinoma, treated with various chemotherapy regimens in our hospital from 1990 to 1999, and carried out a literature review of case reports of thymic carcinoma successfully treated with chemotherapy.
All four cases who received modified ADOC therapy obtained partial responses. Other chemotherapeutic regimens (CHOP-E, PVB) were not effective.
Based on the results of this study and the literature review, we feel that a positive response is obtainable with chemotherapy for thymic carcinoma. Modified ADOC therapy showed consistent efficacy in thymic carcinoma in this study.
与胸腺瘤相比，胸腺癌的预后较差，因为大多数此类肿瘤在诊断时已有局部区域侵犯。因此，胸腺癌治疗的重要步骤是引入全身化疗。然而，由于胸腺癌是一种罕见的肿瘤，化疗治疗尚未得到系统研究。
我们分析了1990年至1999年在我院接受各种化疗方案治疗的7例原发性胸腺癌病例，并对成功接受化疗治疗的胸腺癌病例报告进行了文献综述。
所有接受改良ADOC疗法的4例患者均获得部分缓解。其他化疗方案（CHOP-E、PVB）无效。
基于本研究结果和文献综述，我们认为胸腺癌化疗可获得阳性反应。在本研究中，改良ADOC疗法在胸腺癌中显示出一致的疗效。
